Share Twitter LinkedIn Facebook Email Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).
FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) patients Other 2 Mins Read
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read